Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. PR Newswire LONDON, November 19, 2013 LONDON, November 19, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Monday, November 18, 2013, the S&P 500 ended the day at 1,791.53, down 0.37%; the Dow Jones Industrial Average closed at 15,976.02, up 0.09%; and the NASDAQ Composite finished at 3,949.07, down 0.93%. Shares in the biotechnology industry mostly finished on a negative note, even as the broader market fluctuated between gains and losses. The major movers in the industry included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Sequenom Inc. (NASDAQ: SQNM), Nektar Therapeutics (NASDAQ: NKTR), and Discovery Laboratories Inc. (NASDAQ: DSCO). AAAResearchReports.com has released full comprehensive research on INO, SQNM, NKTR, and DSCO. These free technical analyses can be downloaded by signing up at: http://www.aaaresearchreports.com/register/ Shares in Inovio Pharmaceuticals Inc. plummeted on Monday while the broader market finished on a mixed note. The company's shares closed the day 5.00% lower at $1.90 after fluctuating between $1.87 and $2.05 during the trading session. A total of 2.07 million shares were traded, which is below the daily average volume of 6.64 million. Despite Monday's pullback, the company's shares have gained 31.94% in the previous three months and 1.60% in the last three trading sessions, outperforming the S&P 500, which has gained 8.20% and 0.53% during the respective periods. Additionally, Inovio Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $1.22. Download free report on INO upon registration at: http://www.AAAResearchReports.com/INO111913.pdf Sequenom Inc.'s stock rallied 4.44% on Monday, closing the day at $2.59 after oscillating between $2.51 and $2.68 during the trading session. A total of 3.10 million shares were traded, which is above the daily average volume of 2.95 million. The company's shares have gained 11.64% in the previous three trading sessions and 7.02% in the last one month, outperforming the S&P 500, which has gained 0.53% and 2.70% during the respective periods. Further, Sequenom Inc.'s stock is trading above its 50-day moving average of $2.50. SQNM technical report can be accessed for free by signing up at: http://www.AAAResearchReports.com/SQNM111913.pdf Nektar Therapeutics' stock plummeted on Monday, closing the day at$11.01, down 3.08%, after oscillating between$10.92 and $11.48 during the trading session. A total of 0.69 million shares were traded, which is below the daily average volume of 1.30 million. Despite Monday's losses, the company's shares have advanced 7.52% in the previous one month, compared to a gain of 2.70% in the S&P 500 during the same period. Additionally, Nektar Therapeutics' stock is trading above its 200-day moving average of $10.80. The free report on NKTR can be downloaded by signing up now at: http://www.AAAResearchReports.com/NKTR111913.pdf Shares in Discovery Laboratories Inc. fluctuated between $2.03 and $2.14 before ending the Monday's session 0.97% lower at $2.05. A total of 0.59 million shares were traded, which is below the daily average volume of 0.93 million. Despite Monday's decline, the company's shares have surged 20.59% in the previous three months, outperforming the S&P 500, which has gained 8.20% during the same period. Further, Discovery Laboratories Inc.'s stock is trading above its 200-day moving average of $1.97. A free report on DSCO can be accessed by registering at: http://www.AAAResearchReports.com/DSCO111913.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.AAAResearchReports.com/ SOURCE AAA Research Reports Contact: Contact Name: Peter F. Jones - Phone #: +1(646)396-9126, Email ID: firstname.lastname@example.org
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc.